Literature DB >> 16148167

Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Sandra Romero-Steiner1, Patricia F Holder, Patricia Gomez de Leon, Willie Spear, Thomas W Hennessy, George M Carlone.   

Abstract

Determination of antibody avidity measurements can be difficult in human serum depending on the population evaluated. We evaluated three approaches for the determination of antibody avidity for immunoglobulin G (IgG). These approaches were (i) elution of bound antibody with increasing concentrations of a chaotropic agent using a single serum dilution, (ii) binding interference of multiple serum dilutions by a single concentration of a chaotrope, and (iii) elution of multiple serum dilutions by a single concentration of a chaotrope. Parameters that affect the determination of avidity measurements and their limitations were evaluated with pre- and post-Haemophilus influenzae type b conjugate vaccination sera (n=89). We determined that elution of low-avidity antibodies present in multiple dilutions of the serum sample by a single concentration of a chaotrope (0.15 M sodium thiocyanate [NaSCN]) was optimal for the determination of avidity measurements throughout a wide range of IgG concentrations (0.94 to 304.6 microg/ml). The percent reduction in concentration as determined by the elution assay with 0.15 M NaSCN correlated highly (r=0.84) with weighted averages obtained by an elution assay with multiple solutions of NaSCN. The correlation (r=0.57) between elution and binding interference, when a single concentration of a chaotrope was used, was lower than the correlation between the two elution methods (r=0.84). We found that the serum dilution, the heterogeneity of the antibody population, and the concentration of the chaotrope were the primary variables affecting avidity determinations. In this study, we present multiple analysis methods depending on the methodology used. We also present the factors that affect the analysis of avidity determinations given the polyclonal nature of human sera. This experimental approach should benefit the evaluation of similar antibodies induced by other bacterial polysaccharide vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148167      PMCID: PMC1235792          DOI: 10.1128/CDLI.12.9.1029-1035.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.

Authors:  S Romero-Steiner; D M Musher; M S Cetron; L B Pais; J E Groover; A E Fiore; B D Plikaytis; G M Carlone
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Summary of notifiable diseases--United States, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-06-14       Impact factor: 17.586

3.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

4.  Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

6.  Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay.

Authors:  D V Madore; P Anderson; B D Baxter; G M Carlone; K M Edwards; R G Hamilton; P Holder; H Käyhty; D C Phipps; C C Peeters; R Schneerson; G R Siber; J I Ward; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

7.  Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).

Authors:  S Romero-Steiner; J Fernandez; C Biltoft; M E Wohl; J Sanchez; J Feris; S Balter; O S Levine; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

8.  Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed.

Authors:  Mijke A Breukels; Els Jol-van der Zijde; Maarten J D van Tol; Ger T Rijkers
Journal:  Clin Infect Dis       Date:  2001-12-07       Impact factor: 9.079

9.  Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates.

Authors:  D V Madore; C L Johnson-Kraines; E P Rothstein; D H Smith
Journal:  Curr Med Res Opin       Date:  1999       Impact factor: 2.580

10.  Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine.

Authors:  J Fernández; S Balter; J Feris; E Gómez; Z Garib; P L Castellanos; J Sánchez; S Romero-Steiner; O S Levine
Journal:  Am J Trop Med Hyg       Date:  2000-04       Impact factor: 2.345

View more
  11 in total

1.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

2.  Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Authors:  Henry C Baggett; Thomas W Hennessy; Lisa Bulkow; Sandra Romero-Steiner; Debra Hurlburt; Patricia Holder; Alan J Parkinson; Rosalyn J Singleton; Orin Levine; George M Carlone; Jay C Butler
Journal:  Clin Vaccine Immunol       Date:  2006-06

3.  Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Authors:  Shannon L Harris; How Tsao; Lindsey Ashton; David Goldblatt; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

4.  Effects of Serial Skin Testing with Purified Protein Derivative on the Level and Quality of Antibodies to Complex and Defined Antigens in Mycobacterium bovis-Infected Cattle.

Authors:  W Ray Waters; Mitchell V Palmer; Molly R Stafne; Kristin E Bass; Mayara F Maggioli; Tyler C Thacker; Rick Linscott; John C Lawrence; Jeffrey T Nelson; Javan Esfandiari; Rena Greenwald; Konstantin P Lyashchenko
Journal:  Clin Vaccine Immunol       Date:  2015-04-08

5.  Immunoglobulin G avidities in infants in Mexico after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine.

Authors:  Patricia Gómez-de-León; F Javier Díaz-García; Alberto Villaseñor-Sierra; Jorge Segura; Martha I Carranza; José Luis Arredondo-Garcia; José Ignacio Santos
Journal:  Clin Vaccine Immunol       Date:  2008-04-16

6.  Semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 5.

Authors:  Marilda P Lisboa; Naeem Khan; Christopher Martin; Fei-Fei Xu; Katrin Reppe; Andreas Geissner; Subramanian Govindan; Martin Witzenrath; Claney L Pereira; Peter H Seeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

7.  Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada.

Authors:  Eli B Nix; Kylie Williams; Andrew D Cox; Frank St Michael; Sandra Romero-Steiner; Daniel S Schmidt; William G McCready; Marina Ulanova
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

8.  Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.

Authors:  Ally Olotu; Frederic Clement; Erik Jongert; Johan Vekemans; Patricia Njuguna; Francis M Ndungu; Kevin Marsh; Geert Leroux-Roels; Philip Bejon
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

9.  Identification of antigen-specific B cell receptor sequences using public repertoire analysis.

Authors:  Johannes Trück; Maheshi N Ramasamy; Jacob D Galson; Richard Rance; Julian Parkhill; Gerton Lunter; Andrew J Pollard; Dominic F Kelly
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

10.  Development of Equine IgG Antivenoms against Major Snake Groups in Mozambique.

Authors:  Felipe Raimondi Guidolin; Celso Pereira Caricati; José Roberto Marcelino; Wilmar Dias da Silva
Journal:  PLoS Negl Trop Dis       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.